Problem |
Solutions |
More financing is needed for candidate drugs |
Further investment in neuroscience development |
More patients are needed to participate in clinical trials |
Ability to perform more decentralized neurological disease clinical trials |
Need for better screening solutions in clinical trials |
More sensitive biomarkers to reduce screening failure rate and identify patients who are a good fit |
Need for improved data collection during drug trials to prove drug efficacy |
More robust, granular data to assess small, intraindividual changes in neurocognitive function longitudinally |
Altoida’s mission is to accelerate and improve drug development, neurological disease research, and patient care. To learn more about our precision-neurology platform and app-based medical device, contact us!